Lastly, we report the development of a small molecule inhibitor (PRT382) with enhanced PRMT5 selectivity, improved tolerability, and optimal in vitro and in vivo anti-tumor activity compared to currently available PRMT5 inhibitors. Here, PRMT5 is linked to neoplasm.